SUPN
SUPN clinical trials: Supernus, Inc.
Every trial on ClinicalTrials.gov where Supernus, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 131
- Trials linked
- 118
- As lead sponsor
- 13
- As collaborator
- 3
- Primary completions as lead sponsor, next 90 days
SUPN on the catalyst calendar · SUPN registry changes
- Primary completion Dec 2026Sponsor estimatePhase 3NCT02736656Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule)Supernus Pharmaceuticals, Inc. · Attention-Deficit/Hyperactivity DisorderActive, not recruitingSUPNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 2NCT07226661Double-blind, Placebo-controlled Study in Adults With Major Depressive DisorderSupernus Pharmaceuticals, Inc. · Major Depressive Disorder (MDD)RecruitingSUPNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 31, 2025ActualNo phase registeredNCT05860959SUBLOCADE Long-term OutcomesIndivior Inc. · Opioid Use DisorderCompletedSUPNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2027Sponsor estimatePhase 2NCT07141329SPN-817 Open-Label Extension Study in Adults With Focal Onset SeizuresSupernus Pharmaceuticals, Inc. · Focal Onset SeizuresEnrolling by invitationSUPNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2028Sponsor estimatePhase 4NCT04781140Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHDSupernus Pharmaceuticals, Inc. · Attention-Deficit/Hyperactivity DisorderRecruitingSUPNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2027Sponsor estimatePhase 2NCT06798896RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset SeizuresSupernus Pharmaceuticals, Inc. · Focal Onset SeizuresRecruitingSUPNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2027Sponsor estimatePhase 2NCT05518578Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant EpilepsySupernus Pharmaceuticals, Inc. · EpilepsyRecruitingSUPNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 21, 2026ActualPhase 2NCT06576843INDV-6001 Multiple-Dose Pharmacokinetic StudyIndivior Inc. · Moderate to Severe Opioid Use DisorderCompletedSUPNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 3, 2024ActualPhase 4NCT06185985Open-label Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD and Mood SymptomsSupernus Pharmaceuticals, Inc. · Attention-Deficit/Hyperactivity DisorderCompletedSUPNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 9, 2025ActualNo phase registeredNCT05878210Evaluating the SUBLOCADE Treatment Exit StrategyIndivior Inc. · Opioid Use DisorderCompletedSUPNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 26, 2024ActualPhase 4NCT04995029Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in High-risk UsersIndivior Inc. · Moderate to Severe Opioid-use DisorderCompletedSUPNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 1, 2023ActualPhase 4NCT04050293Therapy for Migraine Prevention in Children 6-11 Years of AgeSupernus Pharmaceuticals, Inc. · Migraine DisordersTerminatedSUPNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 29, 2025ActualPhase 2NCT06384157Proof of Concept and Dose-ranging Study of INDV-2000 in Individuals With Moderate to Severe Opioid Use DisorderIndivior Inc. · Opioid Use DisorderCompletedSUPNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 20, 2025ActualPhase 3NCT05655520A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's DiseaseSupernus Pharmaceuticals, Inc. · Huntington's DiseaseTerminatedSUPNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 23, 2009ActualPhase 2NCT00626236Phase 2a Study of Safety and Tolerability of SPN-810 in Children With ADHD and Persistent Serious Conduct ProblemsSupernus Pharmaceuticals, Inc. · Attention Deficit Disorder With HyperactivityCompletedSUPNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 1, 2027Sponsor estimateNo phase registeredNCT07219927Real-World Patient Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States:Supernus Pharmaceuticals, Inc. · Parkinson DiseaseRecruitingSUPNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 24, 2017ActualPhase 3NCT02942004A Study to Evaluate Efficacy and Safety of SAGE-547 in Participants With Severe Postpartum Depression (547-PPD-202B)Supernus Pharmaceuticals, Inc. · Postpartum DepressionCompletedSUPNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 18, 2017ActualPhase 3NCT02477618A Study With SAGE-547 for Super-Refractory Status EpilepticusSupernus Pharmaceuticals, Inc. · Super-Refractory Status EpilepticusCompletedSUPNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 21, 2023ActualPhase 2NCT05645432An Open-Label Study Evaluating Brexanolone in Adults With TinnitusSupernus Pharmaceuticals, Inc. · TinnitusCompletedSUPNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 5, 2024ActualPhase 2NCT05619692A Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)Supernus Pharmaceuticals, Inc. · Mild Cognitive ImpairmentCompletedSUPNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 29, 2024ActualPhase 2NCT0535882128-Day Study of SAGE-718 on Functioning Capacity in Participants With Huntington's DiseaseSupernus Pharmaceuticals, Inc. · Huntington DiseaseCompletedSUPNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 4, 2024ActualPhase 2NCT05107128A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD)Supernus Pharmaceuticals, Inc. · Huntington's DiseaseCompletedSUPNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 14, 2022ActualPhase 4NCT05059600A Study To Assess The Safe-Use Conditions For Administration of ZULRESSO® in a Home SettingSupernus Pharmaceuticals, Inc. · Postpartum DepressionCompletedSUPNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 28, 2021ActualPhase 2NCT04602624A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to...Supernus Pharmaceuticals, Inc. · Alzheimer DiseaseCompletedSUPNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 25, 2022ActualPhase 2NCT04476017A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Parkinson's Disease Mild Cognitive Impairment (PD-MCI)Supernus Pharmaceuticals, Inc. · Parkinson DiseaseCompletedSUPNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 106 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner